Sugi Predict

Sugi Predict / Compounds / SCHEMBL26314

SCHEMBL26314

SCHEMBL26314

CC(=O)OCCCN(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.56
▸ RAD52 P43351 1/20 0.53
▸ GAA P10253 2/20 0.49
▸ CHRM5 P08912 3/20 0.46
▸ CHRM1 P11229 3/20 0.46
▸ CHRM3 P20309 3/20 0.46
▸ CHRM2 P08172 2/20 0.46
▸ CHRM4 P08173 2/20 0.46
▸ CHRNB2 P17787 2/20 0.46
▸ CHRNA4 P43681 2/20 0.46
▸ TSHR P16473 3/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ PGR P06401 1/20 0.43
▸ HTR1A P08908 1/20 0.43
▸ TBXA2R P21731 1/20 0.43
▸ CHRNB4 P30926 1/20 0.43
▸ CHRNA3 P32297 1/20 0.43
▸ CHRNA7 P36544 1/20 0.43
▸ CHRNA10 Q9GZZ6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL7710348 0.98 ALDH1A1 (0.54) ALDH1A1RAD52GAACHRM5CHRM1
Water SCHEMBL28087308 0.98 ALDH1A1 (0.54) ALDH1A1RAD52GAACHRM5CHRM1
SCHEMBL761115 0.93 ALDH1A1 (0.54) ALDH1A1RAD52GAACHRM5CHRM1
SCHEMBL31440233 0.91 ALDH1A1 (0.52) ALDH1A1RAD52GAACHRM5CHRM1
SCHEMBL34462071 0.91 ALDH1A1 (0.52) ALDH1A1RAD52GAACHRM5CHRM1
SCHEMBL8756090 0.91 ALDH1A1 (0.52) ALDH1A1RAD52GAACHRM5CHRM1
SCHEMBL31297301 0.91 ALDH1A1 (0.52) ALDH1A1RAD52GAACHRM5CHRM1
SCHEMBL31440349 0.91 ALDH1A1 (0.52) ALDH1A1RAD52GAACHRM5CHRM1
SCHEMBL31440335 0.91 ALDH1A1 (0.52) ALDH1A1RAD52GAACHRM5CHRM1
SCHEMBL31440212 0.91 ALDH1A1 (0.52) ALDH1A1RAD52GAACHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3368089-A1 NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES TRANSLATE BIO MA, INC. (US) 2018-09-05 — — EP claimed
WO-2017075038-A1 NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES RANA THERAPEUTICS, INC. (US) 2017-05-04 — — WO claimed
EP-4735415-A1 CALIXARENE COMPOUNDS, THEIR SYNTHESIS AND USE IN PHARMACEUTICAL COMPOSITIONS Phoenix Biosciences SA (BE) 2026-05-06 — — EP disclosed
WO-2025229369-A1 SYNTHETIC NUCLEIC ACID MOLECULES AND USE THEREOF 삼성바이오로직스 주식회사 2025-11-06 — — WO disclosed
US-12297432-B2 Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity TAKEDA PHARMACEUTICALS U.S.A., INC. (US) 2025-05-13 — — US disclosed
EP-4531902-A1 NUCLEIC ACID BASED VACCINE ENCODING AN ESCHERICHIA COLI FIMH ANTIGENIC POLYPEPTIDE CureVac SE (DE) 2025-04-09 — — EP disclosed
WO-2025019903-A1 RNA VACCINES FOR USE IN ANIMAL HEALTH Denteric Pty Ltd (AU) 2025-01-30 — — WO disclosed
WO-2024223953-A1 CALIXARENE COMPOUNDS, THEIR SYNTHESIS AND USE IN PHARMACEUTICAL COMPOSITIONS QUANTOOM BIOSCIENCES S.A. (BE) 2024-10-31 — — WO disclosed
EP-4444885-A2 IRNA COMPOSITIONS AND METHODS FOR SILENCING MYLIP Alnylam Pharmaceuticals, Inc. (US) 2024-10-16 — — EP disclosed
EP-4402261-A1 IRNA COMPOSITIONS AND METHODS FOR SILENCING ANGPTL4 Alnylam Pharmaceuticals, Inc. (US) 2024-07-24 — — EP disclosed
WO-2024125597-A1 COMPOSITIONS AND METHODS FOR INFECTIOUS DISEASES PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) 2024-06-20 — — WO disclosed
US-20070281956-A1 Phenylpyrimidine amines as IgE inhibitors NOVARTIS AG (CH) 2007-12-06 — — US disclosed
US-20070244109-A1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-10-18 — — US disclosed
US-20070244109-A1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-10-18 — — US disclosed
US-20070244197-A1 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2007-10-18 — — US disclosed
US-20070244197-A1 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2007-10-18 — — US disclosed
US-7250443-B2 Pyrrole based inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2007-07-31 — — US disclosed
US-7250443-B2 Pyrrole based inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2007-07-31 — — US disclosed
WO-2007084786-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS NOVARTIS AG (CH) 2007-07-26 — — WO disclosed
US-6201093-B1 MERCAPTO-FUNCTIONAL POLYSILOXANES MODIFIED WITH ETHENICALLY UNSATURATED COMPOUNDS CONTAINING AMINO GROUPS; USE AS TEXTILE FINISHING AIDS, SURFACTANTS AND EMULSIFIERS HUELS AKTIENGESELLSCHAFT (DE) 2001-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244197-A1 Antibacterial agents MRPL21, SI, PGLS ALDH1A1 782/4885RAD52 3409/4885GAA 79/4885
US-20070281956-A1 Phenylpyrimidine amines as IgE inhibitors FCER2, SELP, FCGR2A ALDH1A1 1102/4885RAD52 1836/4885GAA 2341/4885
US-20070244109-A1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 GSK3B, GSK3A, PYGB ALDH1A1 3907/4885RAD52 2771/4885GAA 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.